The Minute Virus of Mice: A New Hope for Pancreatic Cancer Treatment?

Pancreatic ductal carcinoma is one of the most aggressive cancers, often resistant to conventional treatments. Most patients are diagnosed at an advanced stage, rendering traditional therapies ineffective. Therefore, developing new therapeutic strategies is a priority to improve patient outcomes.  

Among promising approaches, oncolytic virotherapy, which uses modified viruses to destroy cancer cells, is gaining attention. Specifically, the minute virus of mice (MVMp), known for its tropism for cancer cells, may represent a novel strategy to target pancreatic tumors.  

This article examines the oncolytic potential of MVMp, detailing its mechanisms of action and its impact on pancreatic cancer cells.

MVMp: A Virus Targeting the Most Aggressive Cancer Cells  

MVMp infection has been studied in vitro and in vivo, using immunodeficient and immunocompetent mouse models. The virus’s effectiveness was observed in both mesenchymal and epithelial pancreatic cell lines, as well as in human-derived pancreatic cancer cells. The effects of MVMp were evaluated based on several parameters: induction of cancer cell death, modification of the tumor microenvironment, and activation of the immune system.  

Firstly, these studies confirm the virus’s selectivity. MVMp preferentially infects mesenchymal-type pancreatic cells.  

MVMp infection is also associated with increased cytotoxicity. The virus induces apoptosis in mesenchymal cells with minimal impact on epithelial cells. Finally, in immunocompetent mice, MVMp slows tumor growth and extends survival while triggering an immune response characterized by the infiltration of cytotoxic T cells and activated macrophages into the tumor.  

The Minute Virus of Mice as a Therapy for Aggressive Pancreatic Cancer  

This study highlights MVMp's potential as an oncolytic agent for pancreatic cancer treatment. Its specificity for mesenchymal tumor cells, its ability to induce cancer cell death, and its capacity to stimulate the immune system make it a promising therapeutic candidate, particularly for the most aggressive forms of pancreatic cancer. More broadly, these findings provide a robust foundation for a precision medicine approach in patients with tumors exhibiting a mesenchymal profile. Additional studies, especially those exploring combinations with immunotherapies, could further enhance MVMp's therapeutic efficacy in treating resistant cancers.